Folkert van Bruggen — the University of Groningen research portal

If you made any changes in Pure these will be visible here soon.

3 Comment/Letter to the editor
1 Article

Evolocumab's Long-Term Mortality Risk Unclear Due to Shortened Follow-Up of FOURIER
van Bruggen, F. H. & Luijendijk, H. J., Jan-2022, In: American journal of cardiovascular drugs. 22, 1, p. 5-8 4 p.
Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review

Open Access
File

1 Citation (Scopus)

26 Downloads (Pure)
Response to Letter to the Editor re: "Serious adverse events and deaths in PCSK9 inhibitor trials reported on ClinicalTrials.gov: a systematic review": 'serious adverse events and deaths in PCSK9 inhibitor trials reported on ClinicalTrials.gov: a systematic review'
van Bruggen, F. H., Nijhuis, G. B. J., Zuidema, S. U. & Luijendijk, H. J., 21-Jan-2021, In: Expert Review of Clinical Pharmacology. 14, 2, 2 p.
Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review

Open Access
File

24 Downloads (Pure)
Serious adverse events and deaths in PCSK9 inhibitor trials reported on ClinicalTrials.gov: a systematic review
van Bruggen, F. H., Nijhuis, G. B. J., Zuidema, S. U. & Luijendijk, H. J., 2020, In: Expert Review of Clinical Pharmacology. 13, 7, p. 787-796 11 p.
Research output: Contribution to journal › Article › Academic › peer-review

Open Access
File

17 Citations (Scopus)

108 Downloads (Pure)
What the diabetes data in the FOURIER trial fail to show
van Bruggen, F. H. & Luijendijk, H. J., Mar-2019, In: Diabetes obesity & metabolism. 21, 3, p. 741-742 2 p.
Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review

Open Access
File

5 Citations (Scopus)

13 Downloads (Pure)